Trial Profile
An Open Label Extension Study Evaluating the Safety of Long Term Dosing of AMG 531 in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Amgen
- 18 Dec 2021 Status changed from recruiting to completed.
- 14 Oct 2021 This trial has been completed in France, according to European Clinical Trials database.
- 14 Apr 2016 This trial was completed in Spain,Hungary, Austria, Slovakia, Poland (end date: 2011-06-28), Czech Republic (end date: 2011-09-28), Denmark, Germany (end date: 2011-02-23), Belgium (end date: 2011-07-18), and in Netherlands according to European Clinical Trials Database record.